


Express Mail Label No. EV804431674US
Date of Deposit: August 1, 2006

Attorney Docket No. VPI/02-131 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/743,563
Confirmation No.: 5056
Filing Date: December 22, 2003
Examiner: Zinna Northington Davis
Group Art Unit: 1625
Applicants: Charrier et al.
For: CASPASE INHIBITORS AND USES THEREOF

August 1, 2006
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.
- ☒ Copies of references Citation Nos. **B1-B8, C1-C11** are attached.
 - ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.
 - ☐ A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.
- (b) ☒ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
 - ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
 - ☒ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
 - ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

Applicants: Charrier et al.
Application No.: 10/743,563

- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Applicants: Charrier et al.
Application No.: 10/743,563


Respectfully submitted,




Jennifer G. Che, Reg. No. 58,035
Agent for Applicants
Lisa A. Dixon, Reg. No. 40,995
Attorney for Applicants
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6525
Fax: (617) 444-6483
Customer No. 27916

I hereby certify that this correspondence and any documents referred to as attached hereto are being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450 on August 1, 2006.

Lisa Romano



Signature



Modified Form 1449/PTO

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/743,563
Filing Date	December 22, 2003
First Named Inventor	Charrier et al.
Group Art Unit	1625
Examiner Name	Zinna Northington Davis
Attorney Docket Number	VPI/02-131 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,756,466	26-May-1998	Bemis et al.			
	A2	4,728,647	1-Mar-1988	Benavides, et al.			
	A3	5,656,627	12-Aug-1997	Bemis et al.			
	A4	5,847,135	08-Dec-1998	Bemis et al.			
	A5	5,716,929	10-Feb-1998	Bemis et al.			
	A6	6,103,711	15-Aug-2000	Bemis et al.			
	A7	5,973,111	26-Oct-1999	Bemis et al.			
	A8	6,420,522	16-Jul-2002	Bemis et al.			
	A9	6,025,147	15-Feb-2000	Bemis et al.			
	A10	20030162993	28-Aug-2003	Mortimore et al.			
	A11	20040019017	29-Jan-2004	Mortimore et al.			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO	98/16502 A1	Warner-Lambert Company	23-Apr-1998		
	B2	WO	98/16505 A1	Warner-Lambert Company	23-Apr-1998		
	B3	WO	96/40647 A1	Prototek Inc.	19-Dec-1996		
	B4	WO	98/18781A2	Versicor Inc.	07-May-1998		
	B5	WO	2000/68188 A1	Texas Biotechnology Corporation	16-Nov-2000		
	B6	WO	2004/058718 A1	Vertex Pharmaceuticals Incorporated	15-July-2004		
	B7	WO	2004/002961 A1	Vertex Pharmaceuticals Incorporated	08-Jan-2004		
	B8	DD	232699 A1	Akademie der Wissenschaften der	5-Feb-1986		X

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Semple, G., et al. "Pyridone-Based Peptidomimetic Inhibitors of Interleukin-1 β -Converting Enzyme (ICE)," <i>Bioorganic & Medicinal Chem. Letters</i> , 7(10):1337-1342 (1997).
	C2	Livingston, D.J. "In Vitro and In Vivo Studies of Ice Inhibitors," <i>J. of Cell. Biochem.</i> , 64(1):19-26 (1997).
	C3	Husain, M. I., et al. "Some New 2-Aryloxymethyl-3-alpha-substituted Carboxymethyl-6,8-substituted-4-Quinazolones As Possible Anticonvulsants," <i>Pharmazie</i> , 37(6):408-410 (1982).
	C4	Hussain, M., Imtiaz, et al. "Some Newer Quinazolones as Possible Anticonvulsants," <i>J. Chem. Soc. Pak</i> , 6(4):211-215 (1984).
	C5	Canonne, P., et al. "Synthesis of chiral 3-substituted 2,4(1H,3H)-quinazolinodiones," <i>Heterocycles</i> , 36(6):1305-1314 (1993).
	C6	Gouilleux, L, et al. "Solid Phase Synthesis of Chiral 3-substituted Quinazoline-2, 4-diones," <i>Tetrahedron, Letters</i> , 37(39):7031-7034 (1996).
	C7	Gordeev, M. F., et al. "A General and Efficient Solid Phase Synthesis of Quinazoline-2, 4-diones," <i>Tetrahedron Letters</i> , 38(10):1729-1732 (1997).
	C8	Prokai-Tatrai, K., et al., "Prodrugs to Enhance Central Nervous System Effects of TRH-like Peptide pGlu-Glu-Pro-NH ₂ ," <i>Bioorg. Med. Chem. Lett.</i> , 13:1011-1014 (2003).
	C9	Narasimhan, R. S., "Synthetic Application of Lithiation Reactions; IX. A Simplified Synthesis of Isocoumarin," <i>Synthesis</i> , 12: 797 (1975).
	C10	Kinder, M. A., et al., "Solid State Photochemistry of Isocoumarins and Isothiocoumarins," <i>Tetrahedron</i> 56: 6763-6767 (2000).
	C11	Revesz, L., et al., "Synthesis of P1 Aspartate-Based Peptide Acyloxymethyl and Fluoromethyl Ketones as Inhibitors of Interleukin-1 β -Converting Enzyme," <i>Tetrahedron Letters</i> , 35 (52):9693-9696 (1994).

Examiner Signature	Date Considered
--------------------	-----------------

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.